

REMARKS/ARGUMENTS

The claims have been divided into Groups as follows:

- Group I: Claims 1-11, 17 and 20, drawn to a peptide having an amino acid sequence of formula I (SEQ ID NO:1): $X_1FGAPX_2X_3$;
- Group II: Claim 12, drawn to a compound comprising the peptide according to claim 1 for use as a medicament;
- Group III: Claims 13-16, drawn to a method for the preparation of a medicament for the prevention of amyloidosis disorder; and
- Group IV: Claims 18 and 19, drawn to a method of treating or preventing diabetic disorder.

The Examiner has also required an election of species as follows:

- a) If Group I or IV is elected, an election of a single disclosed species of peptide with all the variables specifically and clearly defined is required;
- b) If Group II is elected, an election of a single disclosed species of the compound with all the variables of either the structure or the peptide specifically and clearly defined is required; and
- c) If Group III is elected, an election of a single disclosed species of amyloidosis disorder is required.

Applicants elect, without traverse, Group I, Claims 1-11, 17 and 20 (drawn to a peptide having an amino acid sequence of Formula I (SEQ ID NO:1): $X_1FGAPX_2X_3$), for examination.

Applicants also provisionally elect, for examination purposes only, the following specie of Formula I: a peptide having an amino acid sequence of SEQ ID NO:3 (specification pg 9, lines 23-24).

Applicants respectfully submit that the above-identified application is now in condition for examination on the merits, and early notice thereof is earnestly solicited.


Respectfully Submitted,

Customer Number

22850

Tel. (703) 413-3000
Fax. (703) 413-2220
(OSMMN 08/07)

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.
Norman F. Oblon



Justine M. Wilbur

Registration No. 59,678